EnteroMedics (NASDAQ:RSLS) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday, December 1st.
Separately, Zacks Investment Research raised EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 price objective on the stock in a research note on Wednesday, August 23rd.
EnteroMedics (NASDAQ:RSLS) traded down $0.02 during trading hours on Friday, hitting $1.35. The company had a trading volume of 221,500 shares, compared to its average volume of 1,582,051. EnteroMedics has a 12 month low of $1.23 and a 12 month high of $30.41.
EnteroMedics (NASDAQ:RSLS) last posted its earnings results on Tuesday, November 14th. The medical device company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.77). The firm had revenue of $0.36 million during the quarter. EnteroMedics had a negative return on equity of 104.23% and a negative net margin of 4,509.61%. analysts anticipate that EnteroMedics will post -1.97 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “EnteroMedics (RSLS) Upgraded by ValuEngine to Hold” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/13/enteromedics-rsls-lifted-to-hold-at-valuengine.html.
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for EnteroMedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics and related companies with MarketBeat.com's FREE daily email newsletter.